Previous studies have indicated that MK-1775 can selectively inhibit the growth of TP53-deficient cells in human cancers in vivo and in vitro in combination with radiation or chemotherapy and MK-1775 is currently in clinical trials for TP53-deficient tumors in combination with chemotherapy or radiation (Center, 2016; Ku et al., 2017; Leijen et al., 2016; Osman et al., 2015; Rajeshkumar et al., 2011). This evidence concerns the gene TP53 and cancer.